EP3307305A4 - Vaccins adaptatifs ciblés - Google Patents
Vaccins adaptatifs ciblés Download PDFInfo
- Publication number
- EP3307305A4 EP3307305A4 EP16808481.2A EP16808481A EP3307305A4 EP 3307305 A4 EP3307305 A4 EP 3307305A4 EP 16808481 A EP16808481 A EP 16808481A EP 3307305 A4 EP3307305 A4 EP 3307305A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- vaccines
- targeted adaptive
- adaptive
- targeted
- adaptive vaccines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003044 adaptive effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173783P | 2015-06-10 | 2015-06-10 | |
| PCT/US2016/037095 WO2016201377A1 (fr) | 2015-06-10 | 2016-06-10 | Vaccins adaptatifs ciblés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3307305A1 EP3307305A1 (fr) | 2018-04-18 |
| EP3307305A4 true EP3307305A4 (fr) | 2019-05-22 |
Family
ID=57504553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16808481.2A Withdrawn EP3307305A4 (fr) | 2015-06-10 | 2016-06-10 | Vaccins adaptatifs ciblés |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3307305A4 (fr) |
| WO (1) | WO2016201377A1 (fr) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2858679B2 (fr) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Administration pulmonaire d'arnm à des cellules cibles autres que pulmonaires |
| RS57739B1 (sr) | 2013-03-14 | 2018-12-31 | Translate Bio Inc | Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima |
| JP6586075B2 (ja) | 2013-03-14 | 2019-10-02 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| BR112015022855A2 (pt) | 2013-03-14 | 2017-11-07 | Shire Human Genetic Therapies | composições e método para produção de um anticorpo in vitro |
| EP3388834B1 (fr) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Amélioration synergique de l'administration d'acides nucléiques par l'intermédiaire de formulations mélangées |
| JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| US9850269B2 (en) | 2014-04-25 | 2017-12-26 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| WO2017070601A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv) |
| EP4011451A1 (fr) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Vaccins contre le virus respiratoire |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| EP3825400B1 (fr) | 2016-04-08 | 2024-12-25 | Translate Bio, Inc. | Acide nucléique codant multimère et ses utilisations |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| WO2017201342A1 (fr) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| EP3469074B1 (fr) | 2016-06-13 | 2020-12-09 | Translate Bio, Inc. | Thérapie à base d'arn messager pour le traitement de la carence en ornithine transcarbamylase |
| CA3036831A1 (fr) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | Compositions d'arn de haute purete et procedes pour leur preparation |
| EP3528821A4 (fr) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018107088A2 (fr) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| US20190351040A1 (en) * | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Rna cancer vaccines |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2018157009A1 (fr) * | 2017-02-24 | 2018-08-30 | Modernatx, Inc. | Thérapie de dystrophies musculaires à base d'acide nucléique |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
| WO2018170256A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus de l'herpès simplex |
| WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
| EP3595713A4 (fr) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Vaccin contre le virus respiratoire syncytial |
| EP3595676A4 (fr) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| WO2019036682A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Variants d'arn polymérase |
| EP3668979A4 (fr) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | Procédés pour analyse par clhp |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3675817A1 (fr) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Procédés de fabrication de nanoparticules lipidiques |
| WO2019055807A1 (fr) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Vaccins à arn contre le virus zika |
| US11167043B2 (en) | 2017-12-20 | 2021-11-09 | Translate Bio, Inc. | Composition and methods for treatment of ornithine transcarbamylase deficiency |
| EP3746090A4 (fr) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | Vaccins à base d'arn contre le vrs |
| CN111902157B (zh) * | 2018-03-21 | 2023-08-04 | 松阳生技股份有限公司 | 促进局部肌肉增长、减缓或防止局部肌肉萎缩的组合物及其用途 |
| KR102950141B1 (ko) | 2018-08-24 | 2026-04-07 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 정제 방법 |
| WO2020047399A1 (fr) * | 2018-08-31 | 2020-03-05 | Massachusetts Institute Of Technology | Lipidoïdes ionisables et leurs utilisations |
| CA3113025A1 (fr) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Lipides peg et leurs utilisations |
| WO2020061295A1 (fr) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Lipides peg de haute pureté et leurs utilisations |
| WO2020061457A1 (fr) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Préparation de nanoparticules lipidiques et leurs méthodes d'administration |
| WO2020106946A1 (fr) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | Traitement de la fibrose kystique par administration d'arnm nébulisé codant pour la cftr |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| EP4031662A1 (fr) | 2019-09-20 | 2022-07-27 | Translate Bio, Inc. | Arnm codant pour cftr modifiée |
| TWI881028B (zh) * | 2020-01-28 | 2025-04-21 | 美商聯合生物醫學公司 | 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑 |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4274607A1 (fr) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Vaccins contre le virus de la grippe à arn saisonnière |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| WO2023030635A1 (fr) * | 2021-09-02 | 2023-03-09 | BioNTech SE | Test d'activité pour potentiel thérapeutique d'acide nucléique codant |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| CN119563038A (zh) | 2022-05-25 | 2025-03-04 | 旗舰创业创新七公司 | 用于调节免疫应答的组合物和方法 |
| US20250319115A1 (en) | 2022-05-25 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Compositions and Methods for Modulating Cytokines |
| WO2023230570A2 (fr) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions et procédés de modulation de pilotes génétiques |
| AU2023276757A1 (en) | 2022-05-25 | 2024-11-21 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
| CA3254388A1 (fr) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions et procédés de modulation de facteurs de circulation |
| WO2024002985A1 (fr) | 2022-06-26 | 2024-01-04 | BioNTech SE | Vaccin contre le coronavirus |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| CN120647779B (zh) * | 2025-08-20 | 2025-12-02 | 广州千扬生物医药技术有限公司 | 一种蛋白纳米颗粒及其组合物在制备防治肿瘤的药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140206852A1 (en) * | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides |
| WO2015024666A1 (fr) * | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition et vaccin pour le traitement du cancer du poumon |
| WO2015085318A2 (fr) * | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Vaccins adaptatifs ciblés |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2408455B1 (fr) * | 2009-03-20 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibiteurs de la cathepsine pour la prévention ou le traitement de troubles liés à l'obésité |
-
2016
- 2016-06-10 WO PCT/US2016/037095 patent/WO2016201377A1/fr not_active Ceased
- 2016-06-10 EP EP16808481.2A patent/EP3307305A4/fr not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140206852A1 (en) * | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides |
| WO2015024666A1 (fr) * | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition et vaccin pour le traitement du cancer du poumon |
| WO2015085318A2 (fr) * | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Vaccins adaptatifs ciblés |
Non-Patent Citations (6)
| Title |
|---|
| GERGANA GALABOVA ET AL: "Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management", PLOS ONE, vol. 9, no. 12, 4 December 2014 (2014-12-04), pages e114469, XP055579730, DOI: 10.1371/journal.pone.0114469 * |
| NORBERT PARDI ET AL: "mRNA vaccines - a new era in vaccinology", NATURE REVIEWS. DRUG DISCOVERY, vol. 17, no. 4, 12 January 2018 (2018-01-12), GB, pages 261 - 279, XP055524319, ISSN: 1474-1776, DOI: 10.1038/nrd.2017.243 * |
| PATRICK MIDOUX ET AL: "Lipid-based mRNA vaccine delivery systems", EXPERT REVIEW OF VACCINES, vol. 14, no. 2, 12 February 2015 (2015-02-12), GB, pages 221 - 234, XP055439935, ISSN: 1476-0584, DOI: 10.1586/14760584.2015.986104 * |
| S. HOLTKAMP ET AL: "Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells", BLOOD, vol. 108, no. 13, 15 December 2006 (2006-12-15), pages 4009 - 4017, XP055044965, ISSN: 0006-4971, DOI: 10.1182/blood-2006-04-015024 * |
| See also references of WO2016201377A1 * |
| TOMPKINS STEPHEN MARK ET AL: "Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1", EMERGING INFECTIOUS DISE, EID, ATLANTA, GA, US, vol. 13, no. 3, 1 March 2007 (2007-03-01), pages 426 - 435, XP009089369, ISSN: 1080-6040 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3307305A1 (fr) | 2018-04-18 |
| WO2016201377A1 (fr) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3307305A4 (fr) | Vaccins adaptatifs ciblés | |
| EP3076994A4 (fr) | Vaccins adaptatifs ciblés | |
| EP3197057A4 (fr) | Émetteur-récepteur | |
| EP3231644A4 (fr) | Stabilisateur | |
| EP3312431A4 (fr) | Soufflante | |
| EP3196502A4 (fr) | Amortisseur | |
| EP3164840A4 (fr) | Équipement de communication en champ proche amélioré | |
| EP2938045B8 (fr) | Méthode de géolocalisation | |
| EP3171052A4 (fr) | Amortisseur | |
| EP3299636A4 (fr) | Soufflante | |
| HK40036700A (en) | Vaccine | |
| AU2017904499A0 (en) | Vaccine | |
| AU2017900446A0 (en) | Vaccine | |
| AU2016902014A0 (en) | Vaccine | |
| EP3290048A4 (fr) | Agent inducteur de l'immunité | |
| AU2015901481A0 (en) | Schistosoma vaccine | |
| AU2014903634A0 (en) | Targeted Immunomodulation | |
| AU2015905086A0 (en) | RotatingTie | |
| AU2015904941A0 (en) | Cush-Bar | |
| AU2015902954A0 (en) | Totally adjustable wingsail | |
| AU2015904707A0 (en) | Idaz09 ref001 | |
| AU2015904706A0 (en) | YouTune | |
| AU2015904369A0 (en) | Topperupper | |
| AU2015901715A0 (en) | Improved Camber-Inducer | |
| AU2015903992A0 (en) | iiiicoin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20180109 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20190423 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/31 20060101ALI20190415BHEP Ipc: A61K 39/00 20060101AFI20190415BHEP Ipc: A61P 3/06 20060101ALI20190415BHEP Ipc: C12N 9/52 20060101ALI20190415BHEP Ipc: G01N 33/569 20060101ALI20190415BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20191121 |